Amgen will pay $415 million to enhance the Thousand Oaks, California-based biotechnology powerhouse's drug discovery and development capabilities through the acquisition of deCODE Genetics, nearly three years after the Icelandic genome sequencer emerged from bankruptcy (scripintelligence.com, 22 January 2010).
'Beautiful baton pass' as Amgen picks up deCODE to validate drug targets
Amgen will pay $415 million to enhance the Thousand Oaks, California-based biotechnology powerhouse's drug discovery and development capabilities through the acquisition of deCODE Genetics, nearly three years after the Icelandic genome sequencer emerged from bankruptcy (scripintelligence.com, 22 January 2010).
More from Dermatological
• By
CEO Carlos Gallardo tells Scrip the Barcelona-based group has laid the foundations to advance four promising assets that have considerable potential for a variety of dermatological diseases.
• By
Incyte’s JAK1 inhibitor meets the primary endpoint in two Phase III hidradenitis suppurativa trials, but the drug may not be able to supplant established biologic therapies.
• By
Having bested BMS's oral psoriasis drug Sotyktu, the closely watched once-daily IL-23 blocker is going head-to-head with J&J's own autoimmune mega-blockbuster Stelara.
• By
Swiss major gains global rights to preclinical asset as it joins race for MRGPRX2 antagonists in urticaria, where some same-class rivals are already in Phase II.
More from Therapeutic Category
• By
Seeking cell therapy approaches to cure type 1 diabetes, Vertex abandons a candidate encapsulated to avoid immune system detection but hopes to file another candidate for approval in 2026.
• By
A Phase III trial testing the cortisol modulator showed a benefit on PFS and OS in patients with platinum-resistant ovarian cancer.
• By
The UK giant is forecasting peak sales of $5bn plus